Chugai Pharmaceutical Co., Ltd. (CHGCF)

Chugai Pharmaceutical Income Statement

Financials in millions JPY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	1,023,808	997,901	974,493	1,039,247	802,836	633,314
Other Revenue	172,407	172,710	136,874	220,699	196,923	153,632
Revenue	1,196,215	1,170,611	1,111,367	1,259,946	999,759	786,946
Revenue Growth (YoY)	10.29%	5.33%	-11.79%	26.02%	27.04%	14.68%
Cost of Revenue	354,410	339,409	413,306	476,251	338,147	273,465
Gross Profit	841,805	831,202	698,061	783,695	661,612	513,481
Selling, General & Admin	111,845	110,098	112,580	100,760	102,416	94,401
Research & Development	183,739	181,440	174,868	149,626	137,299	117,850
Other Operating Expenses	-10,928	-2,339	-28,561	-	-	-
Operating Expenses	284,656	289,199	258,887	250,386	239,715	212,251
Operating Income	557,149	542,003	439,174	533,309	421,897	301,230
Interest Expense	-54	5	-27	-61	-48	-62
Interest & Investment Income	-	1,027	4,674	52	-	-
Other Non Operating Income (Expenses)	-921	-1	-	-2,134	-2,464	-2,980
EBT Excluding Unusual Items	556,174	543,034	443,821	531,166	419,385	298,188
Pretax Income	556,174	543,034	443,821	531,166	419,385	298,188
Income Tax Expense	160,730	155,717	118,349	156,737	116,390	83,455
Earnings From Continuing Operations	395,444	387,317	325,472	374,429	302,995	214,733
Net Income	395,444	387,317	325,472	374,429	302,995	214,733
Net Income to Common	395,444	387,317	325,472	374,429	302,995	214,733
Net Income Growth	11.38%	19.00%	-13.08%	23.58%	41.10%	36.29%
Shares Outstanding (Basic)	1,646	1,645	1,645	1,645	1,644	1,643
Shares Outstanding (Diluted)	1,646	1,646	1,645	1,645	1,645	1,645
Shares Change (YoY)	0.01%	0.01%	0.01%	0.01%	0.01%	0.03%
EPS (Basic)	240.31	235.39	197.83	227.64	184.29	130.66
EPS (Diluted)	240.29	235.36	197.80	227.57	184.17	130.53
EPS Growth	11.37%	18.99%	-13.08%	23.57%	41.09%	36.24%
Free Cash Flow	395,356	397,185	337,977	181,487	213,657	147,995
Free Cash Flow Per Share	240.24	241.36	205.40	110.30	129.87	89.96
Dividend Per Share	107.000	98.000	80.000	78.000	76.000	55.000
Dividend Growth	32.10%	22.50%	2.56%	2.63%	38.18%	71.88%
Gross Margin	70.37%	71.01%	62.81%	62.20%	66.18%	65.25%
Operating Margin	46.58%	46.30%	39.52%	42.33%	42.20%	38.28%
Profit Margin	33.06%	33.09%	29.29%	29.72%	30.31%	27.29%
Free Cash Flow Margin	33.05%	33.93%	30.41%	14.40%	21.37%	18.81%
EBITDA	583,534	573,668	470,914	564,743	452,765	331,606
EBITDA Margin	48.78%	49.01%	42.37%	44.82%	45.29%	42.14%
D&A For EBITDA	26,385	31,665	31,740	31,434	30,868	30,376
EBIT	557,149	542,003	439,174	533,309	421,897	301,230
EBIT Margin	46.58%	46.30%	39.52%	42.33%	42.20%	38.28%
Effective Tax Rate	28.90%	28.68%	26.67%	29.51%	27.75%	27.99%
Revenue as Reported	1,196,214	-	-	-	-	-

Updated Jan 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.